Two new codes have been created at table XXE, New Technology, Physiological Systems, Measurement, with the Device/Substance/Technology values noted below.
N Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility
Q Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection
Positive Blood Culture Fluorescence Hybridization
Code XXE5XN6, Measurement of infection, positive blood culture fluorescence hybridization for organism identification, concentration and susceptibility, new technology group 6, was created to describe the processing and analysis of a positive blood culture using the Accelerate PhenoTest™ BC kit. The test is a fast, automated, phenotypic, direct-from-positive blood culture identification and antimicrobial susceptibility test that identifies 16 organisms. The organisms are 6 Gram-positive bacteria, 8 Gram-negative bacteria and 2 Candida species. The test also provides antibiotic susceptibility of specific pathogens.
Microorganism identification is performed using fluorescence in situ hybridization. Colocalization of target (green fluorescence) and universal (red fluorescence) probe signals confirm the presence and identity of the target organism while differentiating from non-specific staining. Antimicrobial susceptibility testing (AST) is performed using morphokinetic cellular analysis (MCA) which measures morphological and kinetic changes over time of organisms exposed to antibiotics. The technology provides results produced in approximately 2 hours for the fast diagnosis of bloodstream infection as opposed to standard of care methods that typically take 2-3 days.
Nucleic Acid-base Microbial Detection
Code XXEBXQ6, Measurement of infection, lower respiratory fluid nucleic acid-base microbial detection, new technology group 6, was created to identify the utilization of the BioFire® FilmArray® Pneumonia Panel. The pneumonia panel is a new diagnostic technology that simultaneously identifies 33 clinically relevant targets from sputum (including endotracheal aspirate) and bronchoalveolar lavage (including mini-BAL) samples in approximately an hour compared to standard culture methods that often take days. The test includes eight viral targets, eighteen bacterial targets, and seven antimicrobial resistance gene targets. By providing semi-quantitative results for bacterial targets commonly found colonizing the respiratory tract, the test assists in distinguishing between normal colonization and active infection from these organisms that cause pneumonia and other lower respiratory tract infections.